Navigation Links
Advanced Life Sciences Announces Third Quarter 2008 Financial Results
Date:11/6/2008

2009."

The company ended the third quarter of 2008 with cash and cash equivalents totaling $7.8 million including $1.7 million from the sale of its common stock to Wyeth. Cash usage in the third quarter 2008 was approximately $3.0 million.

Operating Expense Analysis

* Research and development expenses were $11.2 million for the three

months ended September 30, 2008 compared to $3.8 million for the three

months ended September 30, 2007. The increase in R&D expense is

primarily due to the NDA submission milestone payment to Abbott

Laboratories.

* Selling, general and administrative expenses totaled $1.8 million

compared to $2.0 million for the second quarter of last year.

Recent Achievements

* Signed development and commercialization agreement with Wyeth for

cethromycin in Asia Pacific Region;

* Submitted NDA for cethromycin in mild-to-moderate community acquired

pneumonia;

* Entered into debt and equity financing agreements to strengthen the

balance sheet and help fund commitments associated with the NDA

submission and pre-commercialization activities;

* Awarded contract by the Defense Threat Reduction Agency (DTRA) of the

U.S. Department of Defense worth up to $3.8 million to further study

cethromycin as a potential broad-spectrum medical countermeasure over

two years;

* Presented posters and met with cethromycin National Advisory Board at

the October ICAAC/IDSA conference in Washington, DC;

* Announced and initiated collaboration with UK Ministry of Defence to

evaluate the developmental compound ALS-886 as a treatment for

chemically induced lung injury.

Anticipated Fourth Quarter 2008 Milestones

In the fourth quarter 2008, we anticipate achieving the following milestones:

* Advance discussions with prospective U.S. and E.U. partners for the
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Wellinton, Florida (PRWEB) , ... September 02, 2015 ... ... has been treated and managed with the use of special anti-vascular endothelial growth ... occurs in many more patients, currently does not have a scientific protocol for ...
(Date:9/2/2015)... ... September 02, 2015 , ... Drug companies ... compounds. BCC Research reveals in its new report that the U.S. will ... the category and generates the most market demand. , BCC Research examines ...
(Date:9/2/2015)... September 2, 2015 BioLight ... or the "Company"), a firm that invests in, ... cancer diagnostics, announced today that presentations highlighting its ... be delivered at the Ophthalmology Futures European Forum ... of Cataract & Refractive Surgeons ("ESCRS"), both taking ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry Recycling's ... entire waste to energy process and continue to contribute to the sustainability of ... Temarry’s Waste to Energy process has been operating at their Mexico facility, Recicladora ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2
... Mich., Sept. 27 Neogen Corporation,(Nasdaq: NEOG ) ... quarter of,FY 2008, which ended Aug. 31, increased 25% ... a 3-for-2 stock split, net income per,share was $0.21 ... for the,same period in the prior year. First ...
... provides additional treatment option for asthma patients not fully ... ... NAPA, Calif., Sept. 27 Dey, L.P., an,affiliate of Merck ... (zileuton) extended-release tablets with its,marketing partner, Critical Therapeutics, Inc. (Nasdaq: ...
... Systems (NYSE: VAR ) and one of ... IGRT (image guided radiotherapy),training school, enabling hospitals across ... most precise radiotherapy technologies available to radiation,oncologists. ... the venue for,the first event of its kind, ...
Cached Biology Technology:Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues 2Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues 3Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues 4Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues 5Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma 2Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma 3First European IGRT School Takes Place for Radiotherapy Practitioners in UK 2First European IGRT School Takes Place for Radiotherapy Practitioners in UK 3
(Date:8/20/2015)... 20, 2015   Sensory, Inc ., a ... user experience and security of consumer electronics through ... that its TrulySecure™ is the first ... be FIDO Certified™. The FIDO (Fast ... the FIDO UAF (Universal Authentication Framework) 1.0 specifications, ...
(Date:8/19/2015)... 2015  VOXX International Corporation (Nasdaq: VOXX ... a Definitive Agreement to purchase the assets, inclusive ... leader EyeLock through an acquiring entity.  Upon consummation ... interest in the acquiring entity. The closing of ... diligence.  Expanding on its existing supply chain and ...
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... in Earth and Space Sciences More than 2,200 ... and space sciences in Foz do Iguau at the 2010 ... place from 8 to 12 August, are planning 377 scientific ... earthquakes, extreme weather events in the Americas, climate impacts of ...
... a set of ultra-strength cleaners that could be used ... formulas are tough enough to get rid of nerve ... are also non-toxic, based on ingredients found in foods, ... the cleansers appears in ACS, Industrial Engineering and ...
... DNA methylation - an event that affects cell function by ... time by stem cell researchers at UCLA, a finding that ... in human stem cell lines. The team of scientists ... nucleosomes, which compact and regulate access to DNA in the ...
Cached Biology News:2010 Meeting of the Americas, Brazil: News media registration open 22010 Meeting of the Americas, Brazil: News media registration open 32010 Meeting of the Americas, Brazil: News media registration open 4Military develops multi-purpose 'green' decontaminants for terrorist attack sites 2UCLA stem cell researchers uncover previously unknown patterns in DNA methylation 2
QCPN...
... Axima range, the AXIMA-CFR provides a ... sensitivity and mass range, and offers ... reflectron time-of-flight analysis. The unique patented ... of seamless PSD, providing efficient and ...
... creates a new category for MALDI. It ... has been licensed to the PerkinElmerSCIEX joint ... As the first single MALDI-TOF mass spectrometer ... the prOTOF 2000 represents a substantial leap ...
Rat Lung Fibroblasts (RLF) (>500,000 cells)...
Biology Products: